Seeking Alpha

Sinovac Biotech (SVA +3.9%) says a new drug application for its proprietary EV71 vaccine has...

Sinovac Biotech (SVA +3.9%) says a new drug application for its proprietary EV71 vaccine has been filed and accepted by the Beijing Drug Administration. SVA completed the Phase III clinical trials for the vaccine in March, and top-line data showed approximately a 95% efficacy rate against HFMD caused by enterovirus 71. The Administration plans to conduct an on-site inspection and will submit its opinion to China's Food and Drug Administration for further review and evaluation.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector